Can a drug combo wipe out hidden lung cancer cells after surgery?

NCT ID NCT04367311

Ongoing Disease control Sponsor: Nasser Hanna Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II study is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy after lung cancer surgery can clear tumor DNA from the blood. The trial enrolls 100 patients with early-stage non-small cell lung cancer who had detectable tumor DNA after surgery. The goal is to see if this combination reduces the chance of cancer coming back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Atezolizumab (an immunotherapy drug) combined with cisplatin-based chemotherapy
What this could lead to: If successful, this approach could help prevent lung cancer from returning after surgery by using the immune system to target remaining cancer cells.
What could go wrong: This is a mid-stage trial with only 100 participants, so results may not apply to everyone. Immunotherapy can cause immune-related side effects, and the added benefit over standard chemo alone is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER NSCLC

Contacts and locations

Locations

Indiana University Melvin and Bren Simon Cancer Center

Indianapolis, Indiana, 46202, United States
New York University Clinical Cancer Center

New York, New York, 10016, United States
Northwestern University Feinberg School of Medicine

Chicago, Illinois, 60611, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
Penn State Cancer Institute

Hershey, Pennsylvania, 17033, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States
Summit Health

Berkeley Heights, New Jersey, 07922, United States
University of Virginia Health System

Charlottesville, Virginia, 22908, United States
University of Wisconsin

Madison, Wisconsin, 53705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.